A panel of healthcare industry leaders warned Thursday that President Donald Trump’s most favored nations drug pricing policy risks choking off future medical innovation, even as they praised his broader vision of putting patients in control of their healthcare dollars.
“When you have MFN pricing, you give an incentive to the pharmaceutical industry that their investment is not going to pay off in the long run,” Market Institute President Charlie Sauer said at Daily Caller Live’s American Healthcare event at the Waldorf Astoria in Washington, D.C. “As an economist, it’s one of those hard things to look at because how do you look into the future and see what isn’t there?” (RELATED: Eric Hargan Says Kennedy’s Tech Team Won’t Be ‘Scared’ Of AI In Healthcare)
The panel, moderated by Defend Forgotten America founder Jenn Pellegrino, brought together Sauer,…




